TNFRSF12A and pancreatic neoplasm: RG7212, a fully humanized IgG1κ monoclonal antibody that attenuates the binding of Fn14 to TNFSF12, has been shown to inhibit tumor growth in multiple in vivo models, including renal, breast, and pancreatic cancers [85, 86].